1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Concert’s Patient-Reported Outcome Could Help Differentiate Its Alopecia Therapy

 
• By Joseph Haas

Concert’s CTP-543 would be second or third to market in alopecia areata, behind Lilly and likely Pfizer, but the biotech thinks its drug will have the best profile based on efficacy and patient satisfaction.

Alopecia areata
Patient-reported outcome data might be difference maker for Concert's alopecia drug • Source: Shutterstock

Strong patient-reported outcomes in its pivotal trials may help Concert Pharmaceuticals, Inc.’s alopecia areata candidate CTP-543 compete against heavyweights from Eli Lilly and Company and Pfizer Inc.; the deuterated formulation of ruxolitinib (Lilly/Incyte Corporation’s Jakafi) is on track for an early 2023 new drug application filing and is likely to be the third drug approval for the hair-loss condition.

Concert unveiled positive top-line data on 1 August from its Phase III THRIVE-AA2 study, which CEO Roger Tung called confirmatory...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Alkermes Two-For-Two In Narcolepsy As Alixorexton Succeeds In NT2 Trial

 
• By Alaric DeArment

The drugmaker plans to move into Phase III development of the drug, which has now posted positive Phase II results in narcolepsy types 1 and 2.

MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas

Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.

enGene’s Detalimogene On Track For H2 2026 FDA Filing In NMIBC

 
• By Alaric DeArment

The company announced data from patients enrolled after a protocol amendment designed to bring the study in line with non-muscle invasive bladder cancer (NMIBC) standards of care.

A Week Is A Long Time In Biotech, Just Ask Galecto

 
• By Kevin Grogan

A long time on the ropes, the US firm is now well-financed to advance potential candidates for essential thrombocythemia and myelofibrosis into the clinic.

More from R&D

AnaptysBio Scraps Rosnilimab Ulcerative Colitis Trial After Phase II Miss

 
• By Sushmita Panda

The biopharma plans to advance the PD-1 agonist in rheumatoid arthritis despite its failure in ulcerative colitis.

Neurocrine’s Depression Drug Misses In Phase II

 
• By Andrew McConaghie

Small study fails to turn up efficacy signals in the major depressive disorder candidate, leaving Neurocrine with one remaining depression candidate in development.

Beijing Mabworks Scores World-First Phase III Win In Membranous Nephropathy

 
• By Dexter Jie Yan

In a world-first, Beijing Mabworks has scored a Phase III clinical win for its novel anti-CD20 antibody in the treatment of primary membranous nephropathy. However, multiple global contenders including Roche are threatening to come from behind in the race.